Viracta Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
Viracta Therapeutics, Inc. (Nasdaq: VIRX) announced its participation at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 3:00 p.m. EDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Viracta Therapeutics, Inc. (Nasdaq: VIRX) announced its participation at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 3:00 p.m. EDT. The presentation will focus on the company's precision oncology initiatives targeting virus-associated malignancies, particularly its lead product candidate, Nana-val. This all-oral therapy combines nanatinostat and valganciclovir and is currently being evaluated in multiple trials for treating Epstein-Barr virus-positive lymphomas and nasopharyngeal carcinoma. A webcast of the presentation will be available on the Viracta website.
Details
News Market Reaction – VIRX
The recorded move for VIRX in the trading session of this news was +1.42%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, April 7, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company leadership is scheduled to present at the 21st Annual Needham Virtual Healthcare Conference, on Wednesday, April 13, 2022, at 3:00 p.m. EDT.
A webcast of the presentation will be available on the Investors section of the Viracta website under "Events and Webcasts" at https://viracta.investorroom.com/events-and-webcasts. The webcast will be archived for 30 days.
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1) as well as a multinational, open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers.
For additional information please visit www.viracta.com.
Investor Relations Contact:
Ashleigh Barreto
Head of Investor Relations & Corporate Communication
Viracta Therapeutics, Inc.
abarreto@viracta.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/viracta-therapeutics-to-present-at-the-21st-annual-needham-virtual-healthcare-conference-301520133.html
SOURCE Viracta Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.